JPWO2021099783A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021099783A5 JPWO2021099783A5 JP2022529679A JP2022529679A JPWO2021099783A5 JP WO2021099783 A5 JPWO2021099783 A5 JP WO2021099783A5 JP 2022529679 A JP2022529679 A JP 2022529679A JP 2022529679 A JP2022529679 A JP 2022529679A JP WO2021099783 A5 JPWO2021099783 A5 JP WO2021099783A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cbdv
- use according
- hydroxycannabidivarin
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims 7
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 claims 7
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Claims (10)
- 医薬として使用のための、６－ヒドロキシカンナビジバリン（６－ＯＨ ＣＢＤＶ）を含む、組成物。
- ６－ＯＨ ＣＢＤＶが、合成化合物の形態である、請求項１に記載の使用のための組成物。
- ６－ＯＨ ＣＢＤＶが、純粋化合物又は単離化合物の形態である、請求項１に記載の使用のための組成物。
- ６－ＯＨ ＣＢＤＶの用量が、１００ｍｇ／ｋｇ／日より多い、請求項１～３のいずれか一項に記載の使用のための組成物。
- ６－ＯＨ ＣＢＤＶの用量が、１００ｍｇ／ｋｇ／日より少ない、請求項１～３のいずれか一項に記載の使用のための組成物。
- ６－ヒドロキシカンナビジバリン（６－ＯＨ ＣＢＤＶ）及び１以上の薬学的に許容可能な賦形剤を含む、組成物。
- てんかんの治療における使用のための、６－ヒドロキシカンナビジバリン（６－ＯＨ ＣＢＤＶ）を含む、組成物。
- 治療されるてんかんは、哺乳類においてである、請求項７に記載の使用のための組成物。
- 哺乳類はヒトである、請求項８に記載の使用のための組成物。
- 哺乳類は犬である、請求項８に記載の使用のための組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1916977.0 | 2019-11-21 | ||
| GBGB1916977.0A GB201916977D0 (en) | 2019-11-21 | 2019-11-21 | Cannibidol-type cannabinoid compound |
| PCT/GB2020/052944 WO2021099783A1 (en) | 2019-11-21 | 2020-11-18 | Cannabidiol-type cannabinoid compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023503309A JP2023503309A (ja) | 2023-01-27 |
| JPWO2021099783A5 true JPWO2021099783A5 (ja) | 2023-11-29 |
Family
ID=69137226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022529679A Pending JP2023503309A (ja) | 2019-11-21 | 2020-11-18 | カンナビジオール－タイプのカンナビノイド化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11590087B2 (ja) |
| EP (1) | EP4061345A1 (ja) |
| JP (1) | JP2023503309A (ja) |
| KR (1) | KR20220103998A (ja) |
| CN (1) | CN114746086A (ja) |
| AU (1) | AU2020388278A1 (ja) |
| BR (1) | BR112022009580A2 (ja) |
| CA (1) | CA3158192A1 (ja) |
| GB (2) | GB201916977D0 (ja) |
| IL (1) | IL293035A (ja) |
| MX (1) | MX2022006046A (ja) |
| TW (1) | TW202132250A (ja) |
| WO (1) | WO2021099783A1 (ja) |
| ZA (1) | ZA202206386B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| AU2022275207A1 (en) * | 2021-05-12 | 2023-11-30 | GW Research Limited | Rescorcinols, methods for their manufacture, and uses thereof |
| MX2023013250A (es) * | 2021-05-12 | 2023-11-21 | Gw Res Ltd | Derivado de resorcinol como compuesto farmaceuticamente activo y metodo de preparacion del mismo. |
| GB202206506D0 (en) * | 2022-05-04 | 2022-06-15 | Gw Res Ltd | Crystaline forms of a cannabidiol-like cannabinoid |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002512188A (ja) | 1998-04-21 | 2002-04-23 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 抗酸化剤及び神経保護剤としてのカンナビノイド類 |
| US10538373B2 (en) | 2002-08-14 | 2020-01-21 | Gw Pharma Limited | Pharmaceutical formulation |
| TWI583374B (zh) * | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2514054A (en) * | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10441617B2 (en) | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531280A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2551985B (en) | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| CN109106699A (zh) * | 2017-06-23 | 2019-01-01 | 汉义生物科技（北京）有限公司 | 一种用于治疗癫痫的药物组合物、其制备方法及用途 |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB2572126B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572125B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572737A (en) | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB2581517A (en) | 2019-02-22 | 2020-08-26 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2584140A (en) | 2019-05-23 | 2020-11-25 | Gw Res Ltd | Use of cannabidiol in the treatment of epileptic spasms |
| GB2584341B (en) | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| GB2586026A (en) | 2019-07-29 | 2021-02-03 | Gw Res Ltd | Use of cannabidol in the treatment of Dravet syndrome |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
-
2019
- 2019-11-21 GB GBGB1916977.0A patent/GB201916977D0/en not_active Ceased
-
2020
- 2020-11-18 AU AU2020388278A patent/AU2020388278A1/en active Pending
- 2020-11-18 CN CN202080080992.7A patent/CN114746086A/zh active Pending
- 2020-11-18 IL IL293035A patent/IL293035A/en unknown
- 2020-11-18 WO PCT/GB2020/052944 patent/WO2021099783A1/en active Application Filing
- 2020-11-18 JP JP2022529679A patent/JP2023503309A/ja active Pending
- 2020-11-18 MX MX2022006046A patent/MX2022006046A/es unknown
- 2020-11-18 KR KR1020227020695A patent/KR20220103998A/ko unknown
- 2020-11-18 CA CA3158192A patent/CA3158192A1/en active Pending
- 2020-11-18 GB GB2018139.2A patent/GB2590187B/en active Active
- 2020-11-18 EP EP20815903.8A patent/EP4061345A1/en active Pending
- 2020-11-18 BR BR112022009580A patent/BR112022009580A2/pt unknown
- 2020-11-20 TW TW109140702A patent/TW202132250A/zh unknown
-
2022
- 2022-05-13 US US17/743,653 patent/US11590087B2/en active Active
- 2022-06-08 ZA ZA2022/06386A patent/ZA202206386B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017057230A5 (ja) | ||
| JP2022058688A5 (ja) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| BRPI0403935A (pt) | Formas de dosagem de azitromicina com efeitos colaterais reduzidos | |
| NO20013859L (no) | Cyklooksygenase-2 inhibitoriske medikamenter med rask inntreden av terapeutisk virkning | |
| JP2013155188A5 (ja) | ||
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| RU2008137604A (ru) | Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа | |
| JP2017506624A5 (ja) | ||
| JP2002528502A5 (ja) | ||
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| JP2006516571A5 (ja) | ||
| WO2012173581A4 (en) | Thiocolchicoside, etodolac and famotidine combinations | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JPWO2021099783A5 (ja) | ||
| MX2024006271A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2016505050A5 (ja) | ||
| JP2011500589A5 (ja) | ||
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| RU2016137926A (ru) | Композиции грапипранта и способы их применения | |
| JP2003503453A5 (ja) | ガバペンチンおよびプレガバリンを含む相乗作用組成物 | |
| JPWO2021099781A5 (ja) | ||
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| JPWO2021099777A5 (ja) | ||
| JP2019535830A5 (ja) |